Phase 2 Clinical Trial Progress Update

Summary by AI BETAClose X

CRISM Therapeutics Corporation has provided an update on its Phase 2 clinical trial for irinotecan-ChemoSeed in glioblastoma, announcing that its contract manufacturer has successfully produced the first clinical batch of ChemoSeed. While the batch is undergoing final testing, the company is working with its contract research organisation and trial site to complete activation steps for patient dosing. Due to the ongoing site activation process, CRISM Therapeutics is extending its guidance for first patient dosing to the first half of 2026, and will provide further updates on trial commencement as soon as possible.

Disclaimer*

UK 100

Latest directors dealings